Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 4/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307328 | 0.94 | MTNR1A (0.40) | MTNR1AMTNR1B | |
| SCHEMBL4307709 | 0.92 | MTNR1A (0.38) | MTNR1AMTNR1B | |
| SCHEMBL4305341 | 0.92 | MTNR1A (0.38) | MTNR1AMTNR1B | |
| SCHEMBL4315289 | 0.92 | MTNR1A (0.38) | MTNR1AMTNR1B | |
| SCHEMBL4309625 | 0.91 | TSPO (0.43) | TSPOMTNR1AMTNR1B | |
| SCHEMBL4316476 | 0.91 | KDM4E (0.42) | TSPOMTNR1AMTNR1B | |
| SCHEMBL4309415 | 0.90 | MTNR1A (0.37) | MTNR1AMTNR1B | |
| SCHEMBL4308057 | 0.90 | MTNR1A (0.37) | MTNR1AMTNR1B | |
| SCHEMBL4320635 | 0.89 | MC4R (0.43) | TSPOMTNR1AMTNR1B | |
| SCHEMBL4312648 | 0.88 | MTNR1A (0.36) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | claimed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | TSPO 859/4885MTNR1A 425/4885MTNR1B 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.